X-Therma Secures $22.4M for Breakthrough Organ Preservation Technology

X-Therma, a biotech company in San Francisco, has raised $22.4M in Series B funding to advance their regenerative medicine and organ preservation platform. Led by CEO Xiaoxi Wei, the company aims to increase organ availability for transplantation by overcoming time-sensitive limitations. The investment will support the development of key products like XT-Thrive® and XT-NoVoTM for regenerative medicine, as well as XT-ViVo® & TimeSeal® for organ preservation. X-Therma's cold chain technology is set to revolutionize the field and eliminate organ waiting lists globally.